Vivani Medical (VANI) Projected to Announce Quarterly Earnings on Thursday

Vivani Medical (NASDAQ:VANI) is expected to be announcing its Q3 2026 resultson Thursday, November 12th. Analysts expect the company to announce earnings of ($0.07) per share for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Vivani Medical (NASDAQ:VANI) last issued its earnings results on Thursday, August 13th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.01. On average, analysts expect Vivani Medical to post ($0.30) EPS for the current fiscal year and ($0.27) EPS for the next fiscal year.

Vivani Medical Trading Up 1.9%

VANI stock opened at $1.07 on Thursday. The firm has a 50 day moving average of $1.23 and a 200-day moving average of $1.25. Vivani Medical has a 12-month low of $0.92 and a 12-month high of $1.66. The company has a market cap of $96.51 million, a price-to-earnings ratio of -3.06 and a beta of 2.51.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on VANI shares. Weiss Ratings restated a “sell (d-)” rating on shares of Vivani Medical in a report on Friday, October 2nd. Wall Street Zen raised Vivani Medical from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Vivani Medical currently has an average rating of “Hold” and an average price target of $3.75.

Vivani Medical Company Profile

Vivani Medical, Inc is a clinical-stage biopharmaceutical company developing miniature, subcutaneous drug implants designed to provide continuous delivery of medicines over extended periods. Its proprietary NanoPortal technology is intended to address challenges associated with conventional dosing, including frequent injections, daily administration and inconsistent medication adherence.

The company’s development programs have focused primarily on therapies for metabolic diseases. Its NPM-115 program is designed to deliver exenatide for chronic weight management, while NPM-119 is intended to provide continuous exenatide delivery for the treatment of type 2 diabetes.